Larimar Therapeutics (LRMR) Payables (2016 - 2020)
Historic Payables for Larimar Therapeutics (LRMR) over the last 8 years, with Q3 2020 value amounting to $1.3 million.
- Larimar Therapeutics' Payables fell 8801.93% to $1.3 million in Q3 2020 from the same period last year, while for Sep 2020 it was $1.3 million, marking a year-over-year decrease of 8801.93%. This contributed to the annual value of $10.8 million for FY2019, which is 1953.57% up from last year.
- Larimar Therapeutics' Payables amounted to $1.3 million in Q3 2020, which was down 8801.93% from $2.3 million recorded in Q2 2020.
- Larimar Therapeutics' 5-year Payables high stood at $24.0 million for Q1 2018, and its period low was $1.3 million during Q3 2020.
- For the 5-year period, Larimar Therapeutics' Payables averaged around $10.2 million, with its median value being $7.6 million (2020).
- Its Payables has fluctuated over the past 5 years, first soared by 48638.44% in 2018, then tumbled by 8801.93% in 2020.
- Larimar Therapeutics' Payables (Quarter) stood at $6.2 million in 2016, then skyrocketed by 273.64% to $23.0 million in 2017, then tumbled by 60.71% to $9.0 million in 2018, then rose by 19.54% to $10.8 million in 2019, then plummeted by 88.26% to $1.3 million in 2020.
- Its Payables was $1.3 million in Q3 2020, compared to $2.3 million in Q2 2020 and $7.6 million in Q1 2020.